주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기
통합검색
로그인
고객센터
주요메뉴
질환포커스
세계의약뉴스
국내의약뉴스
성상변경내역
약제급여기준 개정내역
제약업계 소식
메디컬포커스
컨퍼런스
CME
근골격계
남성건강
내분비대사계
면역계
비뇨기계
뇌심혈관계
종양
호흡기계
감각기관계
중추신경계
소화기계
감염계
혈액 및 조혈계
미용
기타
최근 해외학술대회의 주요 발표내용을 제공합니다.
컨퍼런스 커버리지
American Academy of Neurology (AAN) 2025 Annual Meeting
05 April - 09 April, 2025, United States
AI-driven, wrist-worn stimulation device reduces essential tremors
2025-05-29
A wrist-worn wearable that harnesses artificial intelligence (AI) for noninvasive modulation of the nervous system appears beneficial in patients with essential tremor, enabling them to regain greater control over their upper limb movements for everyday activities.
AXS-05 delays relapse of Alzheimer's disease agitation
2025-05-29
Treatment with AXS-05 significantly delayed the time to relapse of agitation in patients with Alzheimer’s disease (AD) compared with placebo, according to the phase III ACCORD-2 trial presented at AAN 2025.
DUET boosts LXB potential in narcolepsy or idiopathic hypersomnia
2025-05-29
Data from the phase IV DUET* study presented at AAN 2025 reinforce the potential of low-sodium oxybate (LXB) for the treatment of narcolepsy or idiopathic hypersomnia (IH).
Fremanezumab helps prevent episodic migraine in youths
2025-05-29
The use of fremanezumab is safe and effective for the prevention of episodic migraine (EM) in children and adolescents as young as 6 years old, according to a study presented at AAN 2025.
Inebilizumab shows benefit in patients with gMG
2025-05-29
Treatment with inebilizumab significantly improved generalized myasthenia gravis (gMG) symptoms, as shown by a greater reduction in MG-Activities of Daily Living (MG-ADL) scores, among patients who were acetylcholine receptor antibody-positive (AChR-Ab+) or muscle-specific kinase antibody-positive (MuSK-Ab+), according to the phase III MINT* trial presented at AAN 2025.
Tolebrutinib reduces disability accumulation in relapsing MS
2025-05-29
Treatment with tolebrutinib results in a clear reduction in disability accumulation in patients with relapsing multiple sclerosis (MS) compared with teriflunomide despite no difference in relapses, according to the findings of the GEMINI 1 and 2 trials presented at AAN 2025.
Transnasal cooling a promising drug-free approach to tackling acute migraine attacks
2025-05-29
An investigational neuromodulation device that delivers a controlled flow of dry, room-temperature air through the nasal passage helps relieve migraine pain, as shown in a study.
X-TOLE OLE interim analysis shows long-term efficacy of novel agent for focal epilepsy
2025-05-29
Interim data from the ongoing 7-year open-label extension (OLE) of the phase IIb X-TOLE study reflect the long-term efficacy and safety of azetukalner, an investigational, potent Kv7 potassium channel opener, for the treatment of adults with focal epilepsy.
1
최근 본 콘텐츠
최근 본 콘텐츠가 없습니다
관심제품
관심콘텐츠
